Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.

Article Details

Citation

Copy to clipboard

Tun AM, Ansell SM

Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.

Cancer Treat Rev. 2020 Aug;88:102042. doi: 10.1016/j.ctrv.2020.102042. Epub 2020 May 30.

PubMed ID

32521386 [ View in PubMed

]

Abstract

Since the clinical introduction of anti-CD20 monoclonal antibodies into lymphoma treatment, immunologic approaches in lymphoma have made substantial progress. Advances in our understanding of tumor immunology have led to the development of strategies to overcome immunologic barriers responsible for an ineffective immune response. Specifically, therapeutic agents have been developed and tested against molecules that are responsible for T-cell exhaustion. The use of monoclonal antibodies against immune checkpoints in the adaptive immune system, such as programmed cell death-1 and cytotoxic T-lymphocyte-associated protein 4, has changed the landscape of cancer therapy including the treatment of lymphoma. This achievement has recently been accompanied by the development of novel immune checkpoint inhibitors targeting the innate immune system, including the CD47-SIRPalpha signaling pathway, and this approach has yielded promising results. To overcome impaired antigen presentation, antibody-based cytotoxic strategies, namely antibody-drug conjugates (polatuzumab vedotin and brentuximab vedotin) and bispecific T-cell or NK-cell engagers (blinatumomab, REGN1979, RG6206, and AFM13), have rapidly evolved with promising clinical activity. As additional tools become available for lymphoma treatment, formulation of safe, rational combination strategies to combine them with standard therapy will be of paramount importance. A successful approach to the treatment of lymphoma may require both an optimized anti-tumor immune response as well as effective depletion of malignant lymphoid cells.

DrugBank Data that Cites this Article

Drugs

Odronextamab

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Odronextamab	B-lymphocyte antigen CD20	Protein	Humans	Yes	Binder	Details
Odronextamab	T-cell surface glycoprotein CD3 (Protein Group)	Protein group	Humans	Yes	Binder	Details